R1 RCM — Investor Presentation (May 2021)
40 slides from R1 RCM's investor presentation, May 17, 2021
Slide 1: Investor Presentation May 17, 2021
Investor Presentation May 17, 2021 Exhibit 99.1
Slide 2: Forward-Looking Statements and Non-GAAP Financial Measures
2 Forward-Looking Statements and Non-GAAP Financial Measures This presentation includes information that may constitute “forward-looking statements,” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements relate to future, not
Slide 3: Leading Technology-Driven Platform to Manage Healthcare Provider Revenue
3 Leading Technology-Driven Platform to Manage Healthcare Provider Revenue NPR Under Management $1.3B Revenue CAGR, 2018-2020 >15% Revenue Cycle Platform for Leading Providers Large, Growing Addressable Market Significant Growth Strong Visibility and High Margin Recurring Revenue >90% Note1: CMS NHE
Slide 4: Transforming Revenue Performance Across Care Settings and Payment Models
4 Transforming Revenue Performance Across Care Settings and Payment Models All Revenue Cycle Phases Order to Intake Care to Claim Claim to Payment All Payment Models Fee-for-service Patient Self-pay Value-based Solutions address the full spectrum of needs and operations All Care Settings Ambulatory
Slide 5: Compelling Value Proposition for All Healthcare Providers
5 Compelling Value Proposition for All Healthcare Providers NEED ▪ Higher patient satisfaction ▪ Lower costs ▪ Higher revenue ▪ Faster collections Growing pressure to run revenue cycle more efficiently We plug into healthcare providers’ existing IT systems VALUE ADD RESULTS
Slide 6: Why We Win
6 Why We Win Proprietary Technology Experienced Talent Performance Analytics Proven Results Global Shared Services R1 Infrastructure and Capabilities Flexible Engagement Models Operating Partner Co-Managed Modular
Slide 7: Financial Outlook
7 Financial Outlook Expect to add $4B in new end-to-end NPR under management in 2021 Note: Adjusted EBITDA is a non-GAAP measure, please refer to the Appendix for a reconciliation of non-GAAP financial measures $M Revenue1 Operating Income Adjusted EBITDA 2021 1,410 – 1,460 135 – 155 315 – 330 Mediu
Slide 8: Investment Highlights
8 Investment Highlights 2. Leading Platform for Provider Revenue Management 1. Large and Growing Total Addressable Market 3. Clear and Expanding Competitive Advantage 4. Significant Revenue Growth with High Visibility 4. Deploying Proven Playbook for Margin Expansion5
Slide 9: Evolving Market Dynamics Driving Significant Opportunity
9 Evolving Market Dynamics Driving Significant Opportunity Industry Consolidation Infrastructure not delivering scale advantages Capital Constraints Priority on clinical investments Financial Pressure Declining reimbursement Inflationary labor pressures Increasing Complexity Higher costs
Slide 10: Large, High Growth and Underpenetrated RCM Market
10 Large, High Growth and Underpenetrated RCM Market R1 growing faster than the market at >15% External Spend ~$30B Internal Spend ~$80B Total TAM is $110B1 Acute-Care $70B Physician $40B ~$66B ~$30B External Spend Expected to Double by 20271,2 External Spend Growing >2x Internal Spend2 2020 Externa
Slide 11: Clear and Expanding Competitive Advantage
11 Clear and Expanding Competitive Advantage Platform of Choice Comprehensive Automation Enabling Providers to Power Value-Based Contracts High Quality Low Cost Proven Results Scale Contract Visibility Payment Model Flexibility 1 4 Advanced Intelligent Patient Access Solution Patient Experience Inta
Slide 12: Leading Position to Extend Scale Advantage
12 Leading Position to Extend Scale Advantage Scale advantage ��= Proven operating system + Innovative technology+ Globaldelivery+ Performanceanalytics Platform of Choice 1
Slide 13: Market-Leading Platform to Manage Mission-Critical Process
13 Market-Leading Platform to Manage Mission-Critical Process 1 2 3 4 5 6 7 8 9 10 11 12 13 Pre-Reg./Financial Clearance MD Order & Scheduling Financial Counseling Check-in/ Arrival Quality & HCC Alerts Charge Optimization Coding & Acuity Billing/Claims Processing Payment Posting Under- payments/ Re
Slide 14: Comprehensive Portfolio of Technology Solutions
14 Comprehensive Portfolio of Technology Solutions Access Accuracy Assurance Intelligent Automation Analytics Platform of Choice 1 Order to Intake Care to Claim Claim to Payment PATIENT EXPERIENCE ACCESS LINK INSIGHT PAS CHART MANAGER DECISION POST CONTACT 1 Note1: VisitPay transaction currently pen
Slide 15: Comprehensive Automation of the Revenue Cycle
15 Comprehensive Automation of the Revenue Cycle Transformative Technology for R1; Built-for-Purpose Ecosystem ▪ Platform of expert rules, machine learning, OCR/NLP, RPA, and workflow orchestration expands automation opportunities ▪ Strategic business partnerships with leading RPA platforms enables
Slide 16: Early Innings of Automation and Digitization
16 Early Innings of Automation and Digitization Automation Offerings Robotic Process Automation (RPA) Automation 2 Digital Self-Service Omni-Channel Communications Natural Language Processing Cognitive Automation Web Service Integration ▪ Digital issue resolution ▪ Digital customer service Digital S
Slide 17: A Leading Intelligent Patient Experience Solution
17 Book Intuitive Scheduler ▪ Order & referrals integrated from the start ▪ Patients and providers book in real-time based on true capacity ▪ Built-in proprietary clinical & administrative rules & logic Patient Payments ▪ Seamless payment and billing experience across settings of care ▪ Intuitive pa
Slide 18: VisitPay Overview: Enterprise Patient Payment Platform
18 VisitPay Overview: Enterprise Patient Payment Platform Single solution from intake to back-end billing creates a unified experience for the patient and staff Consolidated household billing across all acute and ambulatory systems, with EOB displayed at visit level; HSA and other insurance informat
Slide 19: VisitPay Transaction Rationale
19 VisitPay Transaction Rationale Accretive to Growth ▪ Accelerates revenue and EBITDA growth trajectory through additional high margin SaaS offering Significant Synergies ▪ Compelling opportunities from increased digital adoption and improved patient yield ▪ Potential for meaningful cross‐sell into
Slide 20: Infrastructure Enabling Providers to Power Value-Based Contracts
20 Infrastructure Enabling Providers to Power Value-Based Contracts Well-positioned to enable providers to take risk Patient Engagement and Referral Management Clinical Documentation and Acuity Capture Revenue Integrity and Payment Administration ▪ Preventive care metric compliance ▪ High-performanc
Slide 21: Value-Based Care Case Study
21 Value-Based Care Case Study Meaningful improvements to an already high-performing medical group Value-Based Contracts 4 HCC Recapture (Reported in Prior Year) New HCC Capture (Suspect Conditions) Annual Wellness Visit (Share of Members) Unaddressed Gaps in Care (Share of Identified Gaps) 68% 62%
Slide 22: Multiple Growth and Profit Drivers
22 Multiple Growth and Profit Drivers Onboard and optimize contracted business Drive digitization and automation Implement new commercial wins Execute targeted M&A
Slide 23: Onboard and Optimize Contracted Wins
23 Onboard and Optimize Contracted Wins Midpoint of adjusted EBITDA contribution margin depending on contracting model: 30% to 45% Steady State Margin 36+ Months 17% to 28% Margin-ramp 12-36 Months -20% to -16% Launch Phase 0-12 Months Note1: $700M NPR End-to-End Operating Partner Physician Group si
Slide 24: Mednax Enterprise Revenue Cycle Management Partnership
24 Mednax Enterprise Revenue Cycle Management Partnership Relationship ▪ End-to-end Operating Partner relationship, won via a competitive process ▪ R1 will be the primary provider of enterprise revenue cycle management services for Mednax ▪ R1 technology to be deployed across Mednax Facilities to dr
Slide 25: Continued Sales Execution to Convert End-to-End Pipeline
25 Continued Sales Execution to Convert End-to-End Pipeline Opportunity to Convert New Commercial Wins to Comprehensive R1 Solution Targeting 10-12% Growth in End-to-End NPR Under Management Over the Next 3-5 Years 2021 Commercial Focus Areas Cross-Sell Opportunities with New Commercial Wins Aggress
Slide 26: Technology Innovation Drives Margin Expansion
26 Technology Innovation Drives Margin Expansion Transformation Measures 2020 Near-Term Objective1 Adjusted EBITDA Contribution ~$20M ~$40M Tasks Automated >30M >60M Machine Learning Models 4 >25 PX Locations Deployed >300 >600 Digital Self-Service Tasks >12M >30M Robotic Process Automation (RPA) Pa
Slide 27: Target Strategic M&A with Significant Synergy Opportunity
27 Target Strategic M&A with Significant Synergy Opportunity M&A is a core competency and key to R1’s growth strategy Opportunity for Outsized Synergies Within $40B+ NPR Strategic Fit Scaled Platform for Synergy RealizationM&A History Physician RCMFeb 2018 June 2020 and Jan 2020 Digitized Scheduling
Slide 28: Delivering High Revenue Growth and Visibility
28 Delivering High Revenue Growth and Visibility Revenue ($M) $869 $1,186 $1,271 2018 2019 2020 >15% CAGR Recurring Revenue (%) >90% >90% Recurring Revenue with weighted average contract life of 9.0 years for end-to-end contracts1 Note1: As of 5/4/2021
Slide 29: Track Record of EBITDA Growth and Margin Expansion
29 6.6% 14.2% 2018 2019 2020 18.9% $57 $168 2018 2019 2020 $240 Track Record of EBITDA Growth and Margin Expansion Adj. EBITDA ($M) >100% CAGR Adj. EBITDA Margin +1,200 BPS
Slide 30: Strong Performance Continues into 2021
30 19.2% 24.0% Q1 2020 Q1 2021 $321 Q1 2020 Q1 2021 Strong Performance Continues into 2021 Revenue ($M) Recurring Revenue (%) 430 BPS $62 Q1 2020 Q1 2021 Adj. EBITDA ($M) Adj. EBITDA Margin 31% 7% $801 23.5% >90% $3421 Note1: Reflects impact of lower volumes due to Covid
Slide 31: Technology Investment Driving Significant Margin Growth
31 Technology Investment Driving Significant Margin Growth Technology Labor and related Adjusted EBITDA margin 2020 Future Objectives1 >30% SG&A <5% Investment Corresponds to Significant Margin Growth ~7% ~19% ~62% ~10% ~20% <45% Note1: Long term (5+ year) objective reflecting impact of digitization
Slide 32: Financial Outlook
32 Financial Outlook Expect to add $4B in new end-to-end NPR under management in 2021 Note: Adjusted EBITDA is a non-GAAP measure, please refer to the Appendix for a reconciliation of non-GAAP financial measures $M Revenue1 Operating Income Adjusted EBITDA 2021 1,410 – 1,460 135 – 155 315 – 330 Medi
Slide 33: Strong Balance Sheet and Streamlined Capital Structure
33 Strong Balance Sheet and Streamlined Capital Structure ▪ In January 2021, R1 executed an agreement to convert all of its Series A Convertible Preferred Stock into common stock – Enhanced alignment among shareholders – Improved cost of capital – Simplified capital structure – Improved share liquid
Slide 34: Investment Highlights
34 Investment Highlights 2. Leading Platform for Provider Revenue Management 1. Large and Growing Total Addressable Market 3. Clear and Expanding Competitive Advantage 4. Significant Revenue Growth with High Visibility 4. Deploying Proven Playbook for Margin Expansion5
Slide 35: Appendix
35 Appendix
Slide 36: Flexible Contracts Have Embedded Growth and Margin Expansion
36 Flexible Contracts Have Embedded Growth and Margin Expansion Various engagement models provide optionality for clients EBITDA margin3 Operating Partner Co-Managed Modular Engagement Type Commentary Illustrative Economics ($M)1 ▪ R1 manages end-to-end RCM capabilities ▪ Requires extensive infrastr
Slide 37: Financial Model for Operating Partner Model
37 Financial Model for Operating Partner Model Illustrative Contribution from $3B NPR Customer Growth • Deploy transition resources • Perform financial assessment • Invest in infrastructure • Implement technology • Finalize employee transitions • Transfers to Shared Services • Complete standardizati
Slide 38: Financial Model for Co-Managed Partner Model
38 Financial Model for Co-Managed Partner Model Illustrative Contribution from $3B NPR Customer Growth • Deploy transition resources • Perform financial assessment • Invest in infrastructure • Implement technology • Complete standardization • Workflow optimization • Rationalize third-party vendors •
Slide 39: Capital Structure Normalization
39 Capital Structure Normalization On January 15, 2021, R1 completed an agreement to convert the preferred stock held by Ascension and TowerBrook to common stock As part of the agreement, the holders received: ▪ 139.3 million common shares ▪ A one-time cash payment of $105 million, funded with cash
Slide 40: Use of Non-GAAP Financial Measures
40 Use of Non-GAAP Financial Measures ▪ In order to provide a more comprehensive understanding of the information used by R1’s management team in financial and operational decision making, the Company supplements its GAAP consolidated financial statements with certain non-GAAP financial performance